Tristan M.
- Country
- France
- Department
- vascular medicine
Research Overview
- Efficacy and Safety of Orforglipron in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety of Prednisone Plus Rivaroxaban Versus Prednisone Alone in Deep Venous Thrombosis of Behçet’s Syndrome: A Randomized Controlled Trial
- Evaluation of Sildenafil Citrate on Claudication Distance in Peripheral Arterial Disease with Intermittent Claudication: A Phase III Randomized Controlled Trial
Data & Insights
Has run more than one trial at 13 of 37 partner sites.
Specializations
Inflammatory Vascular Conditions
The investigator specializes in treating complex vascular inflammatory disorders, with particular emphasis on Takayasu arteritis and its innovative therapeutic approaches.
- Treatment optimization for arterial inflammation
- Biologic therapy applications
- Steroid-sparing strategies
Their work extends to evaluating various immunomodulatory treatments in vascular inflammation management.
Fibrotic Disorders
Focus on the management of idiopathic retroperitoneal fibrosis, particularly investigating optimal treatment durations and monitoring strategies using advanced imaging techniques.
- FDG-PET/CT guided therapy
- Steroid treatment protocols
- Relapse prevention strategies
Their research involves developing precise treatment discontinuation protocols based on imaging biomarkers.
Vascular Medicine
Expert in managing various vascular conditions, including peripheral arterial disease and Behçet's syndrome related complications.
- Intermittent claudication treatment
- Deep venous thrombosis management
- Combined therapeutic approaches
The investigator explores innovative pharmacological interventions for improving vascular function and patient mobility.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.